These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience. Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500 [TBL] [Abstract][Full Text] [Related]
54. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Marty FM; Ljungman P; Papanicolaou GA; Winston DJ; Chemaly RF; Strasfeld L; Young JA; Rodriguez T; Maertens J; Schmitt M; Einsele H; Ferrant A; Lipton JH; Villano SA; Chen H; Boeckh M; Lancet Infect Dis; 2011 Apr; 11(4):284-92. PubMed ID: 21414843 [TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation. Deleenheer B; Spriet I; Maertens J Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172 [TBL] [Abstract][Full Text] [Related]
56. Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis. Chen K; Arbona-Haddad E; Cheng MP; McDonnell AM; Gooptu M; Orejas JL; Timblin K; Silverman E; Al-Hamed R; Soiffer RJ; Hammond SP; Marty FM Transpl Infect Dis; 2021 Aug; 23(4):e13619. PubMed ID: 33866648 [TBL] [Abstract][Full Text] [Related]
57. Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. Chou S; Ercolani RJ; Derakhchan K Antiviral Res; 2018 Sep; 157():128-133. PubMed ID: 30040968 [TBL] [Abstract][Full Text] [Related]
58. Exposure-Response Analyses of Letermovir Following Oral and Intravenous Administration in Allogeneic Hematopoietic Cell Transplantation Recipients. Prohn M; Cho CR; Viberg A; Dykstra K; Davis C; Sabato P; Stone J; Badshah C; Murata Y; Leavitt R; Fancourt C; Macha S Clin Pharmacol Ther; 2022 Feb; 111(2):485-495. PubMed ID: 34674258 [TBL] [Abstract][Full Text] [Related]
59. Use of Letermovir as Salvage Therapy for Drug-Resistant Cytomegalovirus Retinitis. Turner N; Strand A; Grewal DS; Cox G; Arif S; Baker AW; Maziarz EK; Saullo JH; Wolfe CR Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642941 [TBL] [Abstract][Full Text] [Related]
60. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients. Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]